Proven Effective for Treatment-Resistant Depression

SPRAVATO® (intranasal esketamine) is an FDA-approved treatment introduced in 2019 for adults with treatment-resistant depression (TRD) and for major depressive disorder with suicidal thoughts or actions. Kansas Mental Health Medicine is a certified treatment center for the administration and monitoring of SPRAVATO® in a safe, supportive clinical setting.

Proven effective for treatment-resistant depression, SPRAVATO® may benefit adults with clinical depression who have had an inadequate response to two or more antidepressants. SPRAVATO® can now be prescribed with or without an oral antidepressant, depending on each patient’s individualized treatment plan.

To learn more about how SPRAVATO® works and whether it may be right for you, visit the official SPRAVATO® website: SPRAVATO® Treatment Information

close up of young woman with eyes closed

Finding Relief For

The SPRAVATO® short-term studies evaluated efficacy results at 4 weeks

SPRAVATO® in combination with an oral antidepressant

In a 4-week clinical study, patients were given either SPRAVATO® in combination with an oral antidepressant or a placebo nasal spray plus an oral antidepressant. The study showed:

  • Rapid and superior reduction in depression symptoms at ~4 weeks for more patients using SPRAVATO® in combination with an oral antidepressant, as compared with patients who received a placebo nasal spray plus an oral antidepressant*
  • Most of the reduction in depression symptoms was seen at 24 hours
  • Continued improvement between 24 hours and ~4 weeks; the difference in improvement between groups did not appear to increase through 4 weeks

SPRAVATO® alone

Patients in the clinical study were randomly placed into one of two treatment groups receiving either SPRAVATO® alone or placebo alone. The study showed:

  • Rapid and superior reduction in depression symptoms at ~4 weeks and 24 hours for patients using SPRAVATO® alone, as compared to patients who received a placebo nasal spray alone*

*Based on an overall score on a standardized rating scale.

SPRAVATO® was also studied in a long-term, maintenance-of-effect trial

SPRAVATO® in combination with an oral antidepressant

SPRAVATO® was studied to see if the effect of treatment was maintained over time. The study showed:

  • Patients who stayed on SPRAVATO® were less likely to experience a return of depressive symptoms (known as relapse) compared to patients who stopped therapy
  • The trial compared patients who stayed on SPRAVATO® with an oral antidepressant to patients on a placebo nasal spray and oral antidepressant, long-term

Expert Monitoring & Compassionate Care

Administering SPRAVATO® requires specialized certification and a high level of clinical expertise. Meet the dedicated medical professionals who will guide you through your treatment protocol, ensuring your utmost comfort, safety, and progress during every in-office session.

Find Lasting Relief in a Safe Environment.

If two or more antidepressants haven’t adequately worked for you, ask Kansas Mental Health Medicine if SPRAVATO® may be able to help.